omv
Vaccineexperimental
Clinical trial activity
8 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
8
Phase 3
2
Phase 4
0
Earliest trial started Sep 1, 2006 (NCT00381615)
Timeline
Indications
Mechanism of action
- UnclearImmunity, active
Unclear immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- omv
- omv
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02446743 | Phase 3 | Nov 17, 2015 | GlaxoSmithKline |
| NCT02451514 | Phase 2 | Jun 1, 2015 | GlaxoSmithKline |
| NCT02106390 | Phase 3 | Jun 5, 2014 | GlaxoSmithKline |
| NCT01992536 | Phase 2 | Dec 1, 2013 | Novartis |
| NCT01272180 | Phase 2 | Aug 1, 2011 | Novartis |
| NCT01027351 | Phase 2 | Jan 1, 2010 | Novartis |
| NCT00774384 | Phase 2 | Sep 1, 2009 | Novartis, Public Health England, University of Bristol |
| NCT00381615 | Phase 2 | Sep 1, 2006 | Novartis |
Showing 8 of 8 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Novartis | For profit | 5 | 4 | 1 | 2006 |
| GlaxoSmithKline | For profit | 3 | 3 | 2 | 2014 |
| Public Health England | Government | 1 | 0 | 1 | 2009 |
| University of Bristol | Academic/Hospital | 1 | 1 | 1 | 2009 |
4 organizations
Page 1 / 1